Kymera Investor Presentation Deck

KT-474 Reduced IRAK4 in Skin Lesions of AD and HS Patients on Day 28 to at Least Same Level as Healthy Subjects KYMERA Mean (+SE) IRAK4 Levels in Skin (fmol/µg protein) N Mean (± SE) 0.3 0.2 0.1 0.0 MAD Healthy Subjects (Baseline) 46 0.123 (± 0.01) ©2023 KYMERA THERAPEUTICS, INC. ‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒ AD Patients (Baseline) 7 0.216 (± 0.06) HS Patients (Baseline) 11 0.236 (± 0.05) AD Patients (Day 28) 6 0.103 (+ 0.05) ‒‒‒‒‒‒‒‒‒‒‒ ‒‒‒‒‒‒‒‒‒‒‒‒‒‒ HS Patients (Day 28) 9 0.112 (± 0.03) PAGE 17

View entire presentation